First-in-Human Evaluation of the Safety, Tolerability and Pharmacokinetics of the T cell Receptor Signal Modulator AX-158

Share:

D. Scott Batty presented the first-in-human Phase 1 trial results of AX-158 at ACR Convergence 2024, confirming its safety, tolerability, and pharmacokinetics, supporting further clinical studies. Phase 2 data in psoriasis patients is expected later this year.

Request a copy of the poster

Complete the form below to request a digital copy of the poster.

This field is for validation purposes and should be left unchanged.